Scientifically reviewed by
Dr. Ky H. Le, MD
The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.
What began as antimicrobial research has revealed a peptide with surprising versatility. LL-37, the only cathelicidin found in research applications, now attracts scientists studying immunity, wound healing, and cardiovascular disease.
This positively charged antimicrobial peptide disrupts bacterial membranes while activating cellular signaling pathways. Research laboratories use LL-37 to investigate everything from infection resistance to tissue regeneration mechanisms.
Key Research Insights
- LL-37 is the only human cathelicidin peptide that kills bacteria, viruses, and fungi through membrane disruption.
- The peptide activates cellular signaling pathways that control immune responses and tissue repair processes.
- Research shows LL-37 promotes wound healing, blood vessel formation, and cardiovascular protection in laboratory studies.
- Studies indicate LL-37 plays both helpful and harmful roles in cancer, autoimmune diseases, and neurological conditions.
What is LL-37 Peptide?
LL-37 is the only cathelicidin antimicrobial peptide (AMP) and part of the cathelicidin family of host defense peptides (HDP). This 37-amino acid peptide is produced through proteolytic cleavage of human cationic antimicrobial protein 18 (hCAP18) by proteinase 3.
Unlike traditional antimicrobials that target specific pathogens, LL-37 demonstrates broad-spectrum activity against bacteria, viruses, and fungi in laboratory studies. Its research applications extend beyond antimicrobial effects to include immune modulation, angiogenesis, and wound healing mechanisms.
LL-37 carries a net positive charge of +6 and adopts an amphipathic helix structure, making it highly effective for membrane interaction studies and cellular research applications.
? Free LL-37 Research Guide + Exclusive Offers
Subscribe to our community and get a free PDF download that covers everything research professionals need to know about LL-37, plus exclusive discounts and promotions.
How LL-37 Works
LL-37’s biological activity stems from its unique structural properties and receptor interactions.
Membrane Interaction Mechanisms
LL-37 operates through a carpet-like mechanism rather than traditional pore formation. The peptide acts in a detergent-like fashion to disrupt membrane integrity through electrostatic and hydrophobic interactions.
Studies show that LL-37 exhibits two distinct pathways depending on membrane composition[1]. With unsaturated phospholipids, it forms pores, while with saturated phospholipids, it creates helical-rich fibrous structures.
This dual mechanism allows LL-37 to target diverse bacterial membranes. The peptide can penetrate bacterial cells to interact with intracellular targets, including acyl carrier proteins.
Cellular Signaling Pathways
LL-37 influences cellular pathways through receptor-mediated mechanisms. The peptide interacts with formyl-peptide receptor FPR2 to induce cellular migration and activation responses.
Research teams have identified LL-37’s role in activating VEGFA-PI3K/AKT/mTOR signaling pathways. Laboratory studies show this activation promotes cellular proliferation, migration, and tube formation[2].
The peptide also influences NF-κB and MAP kinase signaling cascades. These pathways regulate inflammatory responses and cellular stress responses across different tissue types.
Related Product: Buy LL-37 for laboratory research use.
Research Benefits of LL-37 Peptide
Antimicrobial peptide LL-37 has demonstrated many promising avenues for research applications.
Antimicrobial Properties
Laboratory testing reveals LL-37’s broad-spectrum activity against both Gram-positive and Gram-negative bacteria. The peptide targets pathogens from Pseudomonas, Escherichia, Staphylococcus, and Enterococcus genera.
Key antimicrobial findings include:
- Membrane disruption through electrostatic interactions
- Intracellular target binding to acyl carrier proteins
- Resistance to serum inactivation under physiological conditions
- Concentration ranges vary by bacterial species
Research indicates LL-37 maintains antimicrobial activity even in human serum conditions[3]. This stability makes it valuable for laboratory antimicrobial studies.
Immunity and Immune System Effects
LL-37 functions as a bridge between innate and adaptive immunity responses. The peptide exhibits both pro-inflammatory and anti-inflammatory properties depending on cellular context.
In dendritic cell studies, LL-37 suppresses mature cell function by reducing IL-6 and TNF-α release. Research shows the peptide decreases expression of HLA-DR, CD80, CD83, CD86, and CCR7[4].
For macrophage research, LL-37 directs polarization toward M1 pro-inflammatory phenotypes. The peptide downregulates IL-10 while upregulating IL-12p40 in laboratory models.
Chemotactic studies reveal LL-37 induces neutrophil and eosinophil migration through FPR2 activation. Laboratory data shows increased chemokine production including CXCL8 and MCP-1/CCL-2[5].
Tissue Healing and Repair Studies
LL-37 shows angiogenic properties through direct effects on endothelial cells. Research models show the peptide induces vessel growth with wheel spoke-like structures similar to basic fibroblast growth factor[6].
Wound healing research reveals these mechanisms:
- Keratinocyte migration through epidermal growth factor receptor activation
- TGF-β release from intestinal epithelial cells
- Enhanced cellular proliferation and migration rates
- Improved granulation tissue formation
Clinical studies on diabetic foot ulcers show marked improvements in granulation tissue formation and bacterial colonization reduction[7]. These effects are particularly pronounced in hyperglycemic laboratory conditions.
Cardiovascular Research
LL-37 shows protective effects in cardiovascular research models. Clinical studies indicate higher plasma LL-37 levels predict lower risks of major adverse cardiovascular events[8].
Research findings include:
- Reduced all-cause mortality in post-myocardial infarction models
- Decreased unscheduled revascularization rates
- Anti-hypertrophy effects through NF-κB signaling inhibition
- Cardiac dysfunction attenuation in preclinical models
Laboratory studies using CRAMP (mouse homolog) show decreased levels in heart failure models, while supplementation provides protective effects across research protocols[9].
Metabolic Studies
LL-37 research reveals connections to metabolic regulation. Studies show associations with metabolic syndrome components including obesity, insulin resistance, and dyslipidemia[10].
The peptide influences lipid metabolism through Toll-like receptor activation in adipose tissue research. This activation stimulates pro-inflammatory cytokine secretion and contributes to insulin signaling disruption in laboratory models.
Research teams have identified protective effects against type 2 diabetes through islet amyloid polypeptide (IAPP) aggregation inhibition. LL-37 binds IAPP with high affinity, blocking amyloid formation and reducing pancreatic β-cell damage in research protocols.
Current Research Developments
Research teams are investigating LL-37’s role in autoimmune disease mechanisms. Current studies identify the peptide as a T-cell autoantigen in psoriasis, with two-thirds of patients harboring specific T cells[11].
Scientists are studying post-translational modifications including citrullination and carbamylation. Research shows these modifications link to neutrophil-dominated inflammation and become targets for T-cell responses[12].
Cancer research reveals tissue-specific effects, with LL-37 promoting some tumor types while inhibiting others. Laboratory studies show LL-37 exhibits anticancer effects in colon cancer, gastric cancer, hematologic malignancies, and oral squamous cell carcinoma[13].
Neurological research is investigating LL-37’s brain effects. Studies indicate the peptide may contribute to neurodegenerative processes through chloride intracellular channel 1 activation[14].
In Vitro Research Applications
Research laboratories can utilize LL-37 across multiple experimental applications. The peptide’s diverse biological activities make it valuable for studying cellular mechanisms and disease processes.
| Research Application | Mechanism | Study Focus |
|---|---|---|
| Antimicrobial Testing | Membrane disruption and intracellular targeting | Bacterial resistance mechanisms, broad-spectrum activity |
| Angiogenesis Studies | VEGFA-PI3K/AKT/mTOR pathway activation | Vessel formation, endothelial cell behavior |
| Immune Cell Research | FPR2 receptor signaling and cytokine modulation | Cell migration, inflammatory responses |
| Wound Healing Models | Growth factor receptor activation and cell migration | Tissue repair mechanisms, cellular proliferation |
| Cardiovascular Research | NF-κB signaling and cardiac protection pathways | Heart failure models, protective mechanisms |
Quick Review
Key Takeaway: LL-37 is a promising research tool with applications spanning antimicrobial studies to cardiovascular research, offering laboratories a well-characterized peptide for investigating diverse biological mechanisms and disease processes.
LL-37 research requires high-purity peptides with consistent biological activity. Laboratory protocols depend on pharmaceutical-grade compounds that maintain structural integrity across experimental conditions.
Third-party testing ensures peptide purity and confirms amino acid sequence accuracy for reproducible research results. USA-manufactured LL-37 provides supply chain reliability and quality control standards that support rigorous research protocols.
This content is for research and educational purposes only and LL-37 is not intended for human consumption or therapeutic use.
Scientific Reviewer
This research article has been scientifically reviewed and fact-checked by Dr. Ky H. Le, MD. Dr. Le earned his medical degree from St. George’s University School of Medicine and completed his residency training at Memorial Hermann Southwest Hospital. Board-certified in family medicine with experience in hospital medicine, he brings over two decades of clinical experience to reviewing research content and ensuring scientific accuracy.
About BioLongevity Labs
BioLongevity Labs supplies USA-made research peptides for in vitro laboratory applications. All compounds undergo independent third-party testing to verify purity and composition, with full certificates of analysis available for researchers requiring documentation. Browse our complete peptide catalog to find research-grade peptides for your laboratory needs.
References
- K. E. Ridyard and J. Overhage, “The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent,” MDPI AG, May 2021. doi: 10.3390/antibiotics10060650. https://doi.org/10.3390/antibiotics10060650
- Y. Yang, G. Wu, Y. Wang, Q. Mao, D. Zhang, and J. Wu, “LL37 promotes angiogenesis: a potential therapeutic strategy for lower limb ischemic diseases,” Frontiers Media SA, Apr. 2025. doi: 10.3389/fphar.2025.1587351. https://doi.org/10.3389/fphar.2025.1587351
- Z. OREN, J. C. LERMAN, G. H. GUDMUNDSSON, B. AGERBERTH, and Y. SHAI, “Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity,” Portland Press Ltd., Jul. 1999. doi: 10.1042/bj3410501. https://doi.org/10.1042/bj3410501
- B. Yang et al., “Significance of LL‐37 on Immunomodulation and Disease Outcome,” Wiley, Jan. 2020. doi: 10.1155/2020/8349712. https://doi.org/10.1155/2020/8349712
- J. M. Kahlenberg and M. J. Kaplan, “Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease,” Oxford University Press (OUP), Nov. 2013. doi: 10.4049/jimmunol.1302005. https://doi.org/10.4049/jimmunol.1302005
- R. Koczulla et al., “An angiogenic role for the human peptide antibiotic LL-37/hCAP-18,” American Society for Clinical Investigation, Jun. 2003. doi: 10.1172/jci17545. https://doi.org/10.1172/jci17545
- R. Shi et al., “Self‐assembly of PEG–PPS polymers and LL‐37 peptide nanomicelles improves the oxidative microenvironment and promotes angiogenesis to facilitate chronic wound healing,” Wiley, Nov. 2023. doi: 10.1002/btm2.10619. https://doi.org/10.1002/btm2.10619
- H. Zhao et al., “High Human Antimicrobial Peptide LL-37 Level Predicts Lower Major Adverse Cardiovascular Events after an Acute ST-Segment Elevation Myocardial Infarction,” Japan Atherosclerosis Society, Oct. 2022. doi: 10.5551/jat.63221. https://doi.org/10.5551/jat.63221
- Q. Zhou et al., “The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure,” Ivyspring International Publisher, 2020. doi: 10.7150/thno.46225. https://doi.org/10.7150/thno.46225
- A. D. Popa et al., “Cathelicidin: Insights into Its Impact on Metabolic Syndrome and Chronic Inflammation,” MDPI AG, Dec. 2024. doi: 10.3390/metabo14120672. https://doi.org/10.3390/metabo14120672
- R. Lande et al., “The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis,” Springer Science and Business Media LLC, Dec. 2014. doi: 10.1038/ncomms6621. https://doi.org/10.1038/ncomms6621
- R. Lande et al., “The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis,” Frontiers Media SA, Apr. 2025. doi: 10.3389/fimmu.2025.1546422. https://doi.org/10.3389/fimmu.2025.1546422
- F. Lu, Y. Zhu, G. Zhang, and Z. Liu, “Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy,” Frontiers Media SA, Aug. 2022. doi: 10.3389/fphar.2022.944147. https://doi.org/10.3389/fphar.2022.944147
- X. Chen et al., “Human antimicrobial peptide LL-37 contributes to Alzheimer’s disease progression,” Springer Science and Business Media LLC, Sep. 2022. doi: 10.1038/s41380-022-01790-6. https://doi.org/10.1038/s41380-022-01790-6